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introduced into the vitreous.11 All of the techniques for
maintaining asepsis in the operating room are directed
towards preventing such an event from occurring, but
non-postoperative forms of endophthalmitis are exempt
from these precautions. The third and perhaps most
important issue aVecting visual outcome is the time lapse
between the onset of symptoms and clinical diagnoses and
the initiation of aggressive appropriate therapy. Paradoxi-
cally, time is the only factor over which the clinician has a
small measure of control. The faintest suspicion that the
patient is developing endophthalmitis should lead to the
immediate institution of a standardised diagnostic and
treatment protocol such as the one described by Okhravi
and colleagues in this issue.
Admittedly, there are still questions regarding the stand-
ard of therapeutic care. Are systemic antibiotics really nec-
essary for the treatment of endophthalmitis? Has the ques-
tion of when to do a vitrectomy been definitively answered?
In spite of the results of the Endophthalmitis Vitrectomy
Study12 these grey areas of clinical judgment continue to
weigh heavily on clinicians. Perhaps it is the complex
nature of endophthalmitis itself that prevents a standard
protocol from being devised that can consistently produce
a satisfactory visual outcome in this group of patients that
are so diYcult to treat. Unfortunately, even in the best of
hands the results are still frustrating and the ideal
treatment for endophthalmitis remains elusive.
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Oral administration of antigen in the treatment of eye disease
Feeding antigens to experimental animals can result in oral
tolerance, a peripheral immunological non-responsiveness
induced by the processing of exogenous antigen through
gut associated lymphoid tissue.1 Oral administration of
autoantigen has been shown to ameliorate disease in a
number of rodent models of organ specific autoimmune
conditions including experimental autoimmune uveo-
retinitis (EAU),1–5 experimental autoimmune encephalo-
myelitis (EAE),6 experimental granulomatous colitis,7 and
experimental autoimmune thyroiditis.8 Because antigen
feeding protocols have been shown to be eVective even in
sensitised recipients with established disease, induction of
oral tolerance represents a novel potential strategy for the
treatment of human autoimmune disease, allergy and pos-
sibly graft rejection.
The mechanisms involved in induction and maintenance
of oral tolerance depend critically upon antigen dosage.1 3
Immunisation with high doses of antigen leads to energy of
antigen reactive cells, whereas lower antigen doses induce a
form of immune deviation or active suppression. Anergy
reflects the situation in which antigen reactive cells are
generated but are functionally inactive: the molecular
mechanisms involved are uncertain. Immune deviation
operates through induction of a population of transform-
ing growth factor beta (TGF-â) secreting regulatory T
cells (Th3 cells) which down regulate immune responses,
and by a general skewing towards a Th2 immune response
with production of immunomodulatory cytokines IL-4
and IL-10. In most experimental systems, oral tolerance
can be augmented by covalent coupling of antigen to the
mucosa binding cholera toxin B subunit, which appears to
have a strong adjuvant eVect,9 or by concomitant adminis-
tration of IL-2.5 As with anterior chamber associated
immune deviation (ACAID),10 an intact spleen is necessary
for the induction of oral tolerance to ocular antigen.4 A
detailed review of potential pathways to tolerance in
autoimmune eye disease has recently been provided by
Rizzo and Caspi.11
In 1996, Niederkorn and his colleagues demonstrated
that oral administration of donor type antigen halved the
incidence of murine corneal allograft rejection across
multiple major and minor histocompatibility antigen
mismatches.12 Antigen was administered in the form of tis-
sue cultured, immortalised corneal epithelial and endothe-
lial cells or freshly isolated keratinocytes of donor
phenotype. In this issue of the BJO (p 778), the same
group shows that conjugation of cultured corneal cells to
the cholera toxin B subunit significantly enhances the eY-
cacy of the regimen in prolonging graft survival, with a sin-
gle oral dose of antigen reducing the incidence of corneal
graft rejection by 36%. Multiple oral doses decrease the
incidence of rejection by over 90%. Initiating antigen feed-
ing on the day of corneal transplantation is very eVective
but oral administration of conjugated corneal cells can be
delayed for up to 7 days after corneal transplantation and
still produce a significant (albeit lesser) eVect. Interest-
ingly, administration of exogenous IL-2 has no augmenta-
tive eVect but, as expected, recipient splenectomy abolishes
induction of oral tolerance.
The majority of reported studies on oral administration
of antigen have been performed in rodent models. The
question on everyone’s lips is, of course, will oral immuni-
sation work in humans? In one clinical trial, patients with
multiple sclerosis fed bovine myelin suVered fewer relapses
and demonstrated significantly fewer blood borne antigen
reactive T cells13 and more TGF-â secreting T cells14 than
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did patients fed placebo, although the authors urged
caution in interpreting the results because diVerences in
clinical indices of disease activity did not reach statistical
significance. In a trial of oral administration of avian colla-
gen type II for rheumatoid arthritis, treated patients
showed significant clinical improvement compared with
controls.15 Oral administration of a dust mite extract to
asthmatic patients sensitive to this allergen resulted in
improvement in a variety of objective measures of disease
status.16 Trials of oral administration of uveitogenic retinal
antigen preparations in patients suVering from recurrent
uveitis have recently been reported and are tentatively sup-
portive of this approach.17 Overall, the available evidence
indicates that oral tolerance may be a useful therapeutic
option in some clinical situations.
Assuming oral administration of antigen does tolerise in
the clinical setting, what might constitute a clinically appli-
cable protocol in the context of human corneal transplan-
tation, and is such a protocol actually necessary? The sec-
ond question is straightforward; corneal graft rejection is
the major cause of corneal graft failure in large, longitudi-
nal clinical studies and is a particularly important cause of
graft loss in patients with a history of inflammatory eye
disease.18 A non-toxic, non-pharmacological alternative or
adjunct to existing immunosuppressive drugs for the
prevention of corneal graft rejection would be of major
interest. How could feeding of donor corneal antigen be
accomplished in practice? The use of immortalised
residual corneal epithelial and endothelial cells from a spe-
cific donor would be cumbersome and logistically difficult.
The ethical use of keratinocytes harvested from corneal
donor skin would require extension of current donor con-
sent procedures and presupposes that all important
tolerising epitopes relevant to the cornea are represented in
skin. Although the work of Niederkorn and his colleagues
strongly implicates major and/or minor histocompatibility
complex antigens as the polymorphisms of importance in
oral administration of antigen for experimental corneal
transplantation, every reader will be aware of the
controversy that has surrounded the role of HLA matching
for clinical corneal transplantation. Whether synthetic
major histocompatibility complex allopeptides19 could be
used as a source of antigen for inducing oral tolerance to
corneal grafts is unclear, but possibly worthy of further
experimentation. Such a regimen would, however, require
HLA typing of donor and recipient so that appropriate tol-
erising peptides could be selected for oral administration.
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